Clinical Trial Update: Efficacy and Safety Evaluation of 3K3A-APC in Ischemic Stroke [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating 3K3A-APC for ischemic stroke has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Stroke

Drugs mentioned

• 3K3A-APC (3K3A-activated protein C)

Snippet

Sponsor: ZZ Biotech, LLC | Conditions: Ischemic Stroke | Phase 3 | Status: WITHDRAWN